Chronic hepatitis B virus infection is a major global health problem and the most common cause of liver cancer in the world.

Chronic hepatitis B virus infection is a major global health problem and the most common cause of liver cancer in the world.

The current treatment of chronic HBV infection (CHB) requires the use of nucleotide (t)ide analogs (NUCs) for long-term antiviral inhibition, and these analogs cannot reduce the transcription of episomal and integrated HBV DNA, which leads to the virus Continuous expression of antigens and antigens.

The current treatment of chronic HBV infection (CHB) requires the use of nucleotide (t)ide analogs (NUCs) for long-term antiviral inhibition, and these analogs cannot reduce the transcription of episomal and integrated HBV DNA, which leads to the virus Continuous expression of antigens and antigens.

A study published in Nature Communications found that blocking the activity of ACAT with ACAT ( cholesterol acyltransferase (ACAT) inhibitors can enhance specific immune cells that can resist viruses and related cancerous tumors , proving its role The effectiveness of immunotherapy.

Cholesterol is a type of lipid (fat) that we take in our diet every day, and it can perform a variety of functions in different cells of the human body.

Cholesterol is a type of lipid (fat) that we take in our diet every day, and it can perform a variety of functions in different cells of the human body.

Since ACAT catalyzes the esterification of cholesterol, it can be predicted that its inhibitory effect will reduce the accumulation of neutral lipid droplets in T cells and have a potentially beneficial effect on functionality.

In this study, Professor UCL Maini used human liver disease tissue samples in vitro to show that ACAT inhibition has antiviral activity against hepatitis B virus (HBV) and enhances protective anti-HBV and anti-hepatocellular carcinoma (HCC) T cells.

Then, the Maini research team collaborated with Professor Jane McKeating's laboratory at the University of Oxford to prove that ACAT inhibitors can also block the life cycle of HBV in a way that other antiviral drugs cannot.

Then, the Maini research team collaborated with Professor Jane McKeating's laboratory at the University of Oxford to prove that ACAT inhibitors can also block the life cycle of HBV in a way that other antiviral drugs cannot.

"Using ACAT inhibitors modulate cholesterol metabolism has unique features directly against viruses and tumors, while enhancing the fight against their T cells .

 Dr.

 

Reference: Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint

References: Targeting human Acyl-CoA: cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint in this message